



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



GMB 475

Item No. 40463

CAS Registry No.: 2490599-18-1

Formal Name: (4R)-3-methyl-N-[2-[2-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenoxy]ethoxy]acetyl]-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide

MF: $C_{43}H_{46}F_3N_7O_7S$


FW: 861.9

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GMB 475 is supplied as a solid. A stock solution may be made by dissolving the GMB 475 in the solvent of choice, which should be purged with an inert gas. GMB 475 is sparingly soluble (1-10 mg/ml) in ethanol and soluble (≥ 10 mg/ml) in DMSO.

Description

GMB 475 is a proteolysis-targeting chimera (PROTAC) containing the Bcr-Abl inhibitor GNF-5 (Item No. 16254) conjugated to VHL ligand 1 (Item No. 21591).¹ It induces degradation of Bcr-Abl with a half-maximal degradation concentration (DC_{50}) value of 340 nM. GMB 475 selectively inhibits the proliferation of K562 chronic myeloid leukemia (CML) and Bcr-Abl-expressing Ba/F3 cells ($IC_{50} = \sim 1 \mu\text{M}$ for both) over parental Ba/F3 cells ($IC_{50} = > 10 \mu\text{M}$). It also inhibits the proliferation of Ba/F3 cells expressing mutant Bcr-Abl (IC_{50} s = 1.98 and 0.37 μM for Bcr-Abl^{T315I} and Bcr-Abl^{G250E}, respectively). GMB 475 (2.5 μM) induces apoptosis in primary human CML cells.

Reference

1. Burslem, G.M., Schultz, A.R., Bondeson, D.P., et al. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. *Cancer Res.* **79**(18), 4744-4753 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM